Mal- (CH2) 5-Val-Cit-PAB-Eribulin
Mal- (CH2) 5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal- (CH2) 5-Val-Cit-PAB[1].
Product Specifications
CAS Number
2130869-21-3
UNSPSC
12352203
Target
Drug-Linker Conjugates for ADC
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mal-ch2-5-val-cit-pab-eribulin.html
Purity
99.82
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=C1C[C@](O[C@@]1([H])CC[C@](C[C@H]2C)([H])O[C@](C2=C)([H])C[C@@](O[C@@H]3C[C@H](O)CNC(OCC(C=C4)=CC=C4NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C5=O)C(C=C5)=O)=O)=O)=O)=O)([H])[C@]([C@H]3OC)([H])CC6=O)([H])CC[C@@]7(C[C@@]8([H])O9)O[C@]([C@](O[C@](C6)([H])CC%10)([H])[C@@]%10([H])O%11)([H])[C@@]9([H])[C@]%11([H])[C@@]8([H])O7
Molecular Formula
C69H97N7O19
Molecular Weight
1328.54
References & Citations
[1]Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. Patent US20170252458A1.|[2]Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10 (2) : 161-174.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040460-100 1x 100 µL
CD44 Standard (156-3C11), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400003-100 1x 100 µL
CD45RO (UCHL-1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680460-100 1x 100 µL
CD44 Standard (156-3C11), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details